Opinion on Pharmaceuticals and Healthcare in Slovenia

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002

« | 1 | » »|

No help is available.